zs pharma acquired

AstraZeneca announced today the successful completion of the tender offer for all of the outstanding shares of ZS Pharma (NASDAQ: ZSPH) and the subsequent acquisition of ZS Pharma as previously announced in November. AstraZeneca acquires ZS Pharma Peter Toogood, investment director at City Financial Investment Company Limited, explains why large pharmaceuticals tend to take over midcap rivals. Nov. 6, 2015. AstraZeneca has completed its $2.7-billion acquisition of ZS Pharma, bolstering its cardiovascular and metabolic disease portfolio. AstraZeneca has completed the acquisition of the entirety of Bristol-Myers Squibb’s interest in the companies’ diabetes alliance. Most recently, Ms. Krehlik held VP HR positions at ZS Pharma (acquired by AstraZeneca), Hyperion Therapeutics (acquired by Horizon Pharma) and InterMune (acquired by Roche Genentech). One of the innovative medicines currently in Phase III development is roxadustat as a potential therapy for anaemia associated with chronic kidney disease, in patients on dialysis and those who are not on dialysis. The approval is supported by data from the Phase III GRECO trial and the Phase I AMES trial. ZS Pharma was acquired by AstraZeneca on November 5, 2015. 18th December 2015. by. The transaction is not subject to a financing condition. The safety and tolerability of Fasenra in these trials were consistent with…, Media Value Postal address: Kindstugatan 1, 111 31 Stockholm. Life Science Company. AstraZeneca said today it will acquire ZS Pharma for approximately $2.7 billion, in a deal designed to expand the buyer’s cardiovascular and metabolic disease portfolio. This page shows the latest ZS Pharma news and features for those working in and with pharma, biotech and healthcare. ASTRAZENECA AND ZS PHARMA DISCLAIM ANY INTENT OR OBLIGATION TO UPDATE ANY FORWARD-LOOKING STATEMENTS AS A RESULT OF DEVELOPMENTS OCCURRING AFTER THE DATE HEREOF OR OTHERWISE. Cynthia Smith has more than 20 years of broad leadership experience within the healthcare industry. Transaction Name AstraZeneca’s strategy focuses on reducing morbidity, mortality and organ damage by addressing multiple risk factors across cardiovascular disease, diabetes and chronic kidney disease. Prior to joining Aimmune, Kevin was Vice President, Market Access and Commercial Development at ZS Pharma (acquired by AstraZeneca), where he was instrumental in launching Lokelma ®, the company’s first therapeutic to treat hyperkalemia. AstraZeneca announced today that it has entered into a definitive agreement to acquire ZS Pharma (NASDAQ: ZSPH), a biopharmaceutical company based in San Mateo, California. 1100 … Hyperkalemia Specialist at ZS Pharma, Inc. (acquired by AstraZeneca) United States Sports Academy View profile View profile badges LinkedIn © 2021; About Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed. ZS-9 complements the Company’s increasing focus on CKD and CHF, including the investigational medicine roxadustat, which is currently in Phase III development for patients with anaemia associated with CKD, as well as its leading diabetes portfolio, a comorbidity often associated with CKD and CHF patients. ZS Pharma was acquired by AstraZeneca for $2.7B on Nov 6, 2015. Current estimates for global peak year sales of ZS-9 exceed $1 billion. ZS-9 complements the company’s increasing focus on CKD and CHF, including the investigational medicine roxadustat, which is currently in Phase III development for patients with anaemia associated with CKD, as well as its leading diabetes portfolio. Find out what works well at ZS Pharma, Inc. from the people who know best. ZS Pharma represents a strong fit with AstraZeneca’s pipeline and portfolio in Cardiovascular & Metabolic Disease, one of the company’s three main therapy areas. After multiple rejections, the U.S. Food and Drug Administration (FDA) finally gave its approval for the treatment that was the primary focus of the 2015 $2.7 billion acquisition of ZS Pharma. Health Care. IF UNDERLYING ASSUMPTIONS PROVE INACCURATE OR UNKNOWN RISKS OR UNCERTAINTIES MATERIALIZE, ACTUAL RESULTS AND THE TIMING OF EVENTS MAY DIFFER MATERIALLY FROM THE RESULTS AND/OR TIMING DISCUSSED IN THE FORWARD-LOOKING STATEMENTS, AND YOU SHOULD NOT PLACE UNDUE RELIANCE ON THESE STATEMENTS. AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. Dr. McKearn holds a Ph.D. in Immunology from the University of Chicago and a Bachelor of Science (B.S.) The global development programme is being conducted by FibroGen in collaboration with AstraZeneca and Astellas. SOME OF THE STATEMENTS CONTAINED IN THIS ANNOUNCEMENT ARE FORWARD LOOKING STATEMENTS, INCLUDING THE POSSIBILITY THAT THE TRANSACTION WILL NOT BE COMPLETED AND OTHER RISKS AND UNCERTAINTIES DISCUSSED IN ZS PHARMA’S PUBLIC FILINGS WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION (SEC), INCLUDING THE “RISK FACTORS” SECTIONS OF ZS PHARMA’S ANNUAL REPORT ON FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2014 AND SUBSEQUENT QUARTERLY REPORTS ON FORM 10-Q, AS WELL AS THE TENDER OFFER DOCUMENTS FILED BY SUBSIDIARIES OF ASTRAZENECA AND THE SOLICITATION/RECOMMENDATION STATEMENT FILED BY ZS PHARMA. Before ZS Pharma, he held commercial leadership roles at Exelixis and Genentech, where he launched multiple new products and line extensions in oncology and … THESE STATEMENTS ARE GENERALLY IDENTIFIED BY WORDS OR PHRASES SUCH AS “BELIEVE,” “ANTICIPATE,” “EXPECT,” “INTEND,” “PLAN,” “WILL,” “MAY,” “SHOULD,” “ESTIMATE,” “PREDICT,” “POTENTIAL,” “CONTINUE” OR THE NEGATIVE OF SUCH TERMS OR OTHER SIMILAR EXPRESSIONS. You are about to access AstraZeneca historic archive material. AZ completes acquisition of ZS Pharma. District Sales Manager at ZS Pharma, acquired by AstraZeneca Division Sales Manager at ZS Pharma, acquired by AstraZeneca The University of Texas at Austin AstraZeneca has entered into a definitive agreement to acquire ZS Pharma, a biopharmaceutical company based in San Mateo, California. The FDA approved Lokelma, (sodium zirconium cyclosilicate), formerly ZS-9, for the treatment of adults with hyperkalemia. A submission for European Marketing Application Authorisation is also progressing as planned. Prior to joining Adicet, Ms. Krehlik served in HR leadership roles across a variety of industries and with companies at various stages of growth. ZS Pharma General Information Description. In December last year, the news about the acquisition were announced and on February 1 2014 the deal was completed. Our country sites can be located in the AZ Network. Within the category are a number of drugs including the late-stage roxadustat – an anemia treatment co-developed with partnering company, FibroGen – and early-stage therapies for acute coronary syndrome, diabetes and diabetic kidney disease. Under the terms of the merger agreement, AstraZeneca will commence a tender offer to acquire all outstanding shares of ZS Pharma’s common stock. This website is intended for people seeking information on AstraZeneca's worldwide business. About AstraZeneca in Cardiovascular & Metabolic Disease (CVMD). ZS Pharma serves customers in the United States. 02:09 LONDON — The British drug maker AstraZeneca said on Friday that it had agreed to acquire ZS Pharma, a California-based biopharmaceutical company, for $2.7 billion in cash. You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. AstraZeneca completes acquisition of ZS Pharma. The transaction will give AstraZeneca access to the potassium-binding compound ZS-9, a potential best-in-class treatment for hyperkalaemia, a condition associated with increased mortality in CKD and CHF. He previously served on the boards of Lumena Pharmaceuticals, Inc. (acquired by Shire Plc), Otonomy, Inc. (IPO) and ZS Pharma, Inc. (acquired by AstraZeneca Plc). ZS Pharma acquired by AstraZeneca. We look forward to welcoming the ZS Pharma team to AstraZeneca.”. With this acquisition Fujifilm aims to accelerate the growth of its Bio CDMO business. SUB-INDUSTRY. Subject to customary conditions, including the tender of a majority of the outstanding ZS Pharma shares and the expiration or earlier termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, the transaction is expected to close by the end of 2015. FOUNDED. 17 December 2015. 02/05/2008. Our patient-led strategy is focused on addressing the multiple risk factors facing CVMD and CKD patients at different stages of their disease, with the goal of reducing morbidity and mortality through life changing medicines. Acquired Organization: ZS Pharma ZS Pharma develops ion trap therapies for the treatment of life-threatening medical conditions such as hyperkalemia and liver diseases. Under the terms of the agreement, AstraZeneca will acquire all of the outstanding capital stock of ZS Pharma for $90 per share in an all-cash transaction, or approximately $2.7 billion in aggregate transaction value. Phone: +46 8 588 941 50, AstraZeneca completes acquisition of BMS diabetes share, Fujifilm acquires Danish biologics unit from Biogen for $890 million, AstraZeneca’s Fasenra approved in the US for self-administration in a new pre-filled auto-injector. Health Care. THESE STATEMENTS ARE BASED ON CURRENT EXPECTATIONS, ASSUMPTIONS, ESTIMATES AND PROJECTIONS, AND INVOLVE KNOWN AND UNKNOWN RISKS, UNCERTAINTIES AND OTHER FACTORS THAT MAY CAUSE RESULTS, LEVELS OF ACTIVITY, PERFORMANCE OR ACHIEVEMENTS TO BE MATERIALLY DIFFERENT FROM ANY FUTURE STATEMENTS. ZS Pharma, founded in 2008, is a publicly traded biopharmaceutical company dedicated to challenging the status quo in disease states where therapeutic options have been limited. Prior to ZS Pharma, Robert was a Director at Alta Partners, a venture capital firm located in San Francisco. The tender offer expired at 00:00 EST on 16 December 2015 and was not extended. The deal will give AstraZeneca access to ZS Pharma's treatment for hyperkalemia, a condition of elevated potassium in the bloodstream that is associated with chronic kidney disease and chronic heart failure. ZS Pharma uses its proprietary ion­-trap technology to develop novel treatments for hyperkalaemia (high potassium levels), a serious condition of elevated potassium in the bloodstream, typically associated with chronic kidney disease (CKD) and chronic heart failure (CHF). Selina McKee. ZS is a professional services firm that works side by side with companies to help develop and deliver products that drive customer value and company results. In December the company announced its intention to acquire the respiratory portfolio of Takeda Pharmaceutical – namely Alvesco and Omnaris – for US$575 million [56] A day later, the company announced it had taken a 55% majority stake in Acerta for US$4 billion. ZS Pharma, founded in 2008, is a privately held specialty pharmaceutical company based in Coppell, Texas and Menlo Park, CA. ZS Pharma’s (Nasdaq: ZSPH) stock jumped more than 40 percent after news broke Friday morning that the company was being acquired by global … ZS-9 is under regulatory review by the US Food and Drug Administration with a Prescription Drug User Fee Act goal date of 26 May 2016. The drug joined AstraZeneca’s portfolio when the company acquired its original developer ZS Pharma in 2015 for $2.7 billion. We encourage you to read the privacy policy of every website you visit. The largest life science acquisition in 2015 was Allergan - which was acquired by Allergan for $70.5B. A metabolic disorder, Hyperkalemia is a life-threatening illness caused by the … Large-scale biologics manufacturing site located in Hillerød Fujifilm has entered into an agreement to acquire the…, The US Food and Drug Administration (FDA) has approved the self-administration of Fasenra (benralizumab) in a pre-filled, single-use auto-injector (the Fasenra Pen). The Board of Directors of ZS Pharma has unanimously approved the terms of the agreement. On 6 November it was reported that AstraZeneca had acquired ZS Pharma for US$2.7 billion. All shares that were validly tendered and not withdrawn pursuant to the tender offer were accepted for payment today. Prior to ZS Pharma, Dr. Alexander was a Director at Alta Partners, a venture capital firm, and was also Executive Chairman and interim CEO of SARcode Bioscience. AstraZeneca made the decision to acquire ZS Pharma in an effort to bolster its cardiometabolic disease offerings. Pascal Soriot, Chief Executive Officer of AstraZeneca, said: “Hyperkalaemia can be a life-threatening condition for patients with chronic kidney disease and chronic heart failure, however the risk is underappreciated and prevalence is increasing. Overview. Following completion of the merger, ZS Pharma’s shares ceased to be listed on NASDAQ, and ZS Pharma became a wholly owned subsidiary of AstraZeneca. He previously served on the boards of Lumena Pharmaceuticals (acquired by Shire), Otonomy (NASDAQ: OTIC) and ZS Pharma (NASDAQ: ZSPH; acquired by AstraZeneca). Upon completion, ZS Pharma, which has around 200 employees across three sites in California, Texas and Colorado, will become a wholly owned subsidiary of AstraZeneca. During his time at Alta, he led investments in SARcode Biosciences (acquired by Shire), Sonexa Therapeutics, Allakos, Lumena Pharmaceuticals and ZS Pharma. For more information, please visit: www.zspharma.com. in Biology from the Northern Illinois University. Summary. Save. In connection with the merger, each outstanding share of ZS Pharma that was not accepted for payment in the tender offer (excluding shares held as treasury stock and any shares as to which appraisal rights have been validly exercised under Delaware law) were cancelled and converted into the right to receive $90.00 per share in cash, without interest and less any required withholding taxes, the same as the tender offer price. Uncover why ZS Pharma, Inc. is the best company for you. This acquisition complements our strategic focus on Cardiovascular and Metabolic Disease by adding a potential best-in-class treatment to our portfolio of innovative medicines. Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD - Cardiovascular and Metabolic Disease, ING - Infection, Neuroscience and Gastrointestinal. Compare pay for popular roles and read about the team’s work-life balance. According to the agreement, AstraZeneca gets ownership of the intellectual property and global rights…, Vigilant Biosciences, Inc., has entered into a three-year exclusive sales and marketing agreement with Biotech-IgG AB for the distribution of the OncAlert Oral Cancer Risk Assessment System in Denmark, Norway and Sweden. Prior to joining Aimmune, Kevin was Vice President, Market Access and Commercial Development at ZS Pharma (acquired by AstraZeneca), where he was instrumental in launching Lokelma®, the company’s first therapeutic to treat hyperkalemia. SECTOR. The news marks a further blow for a program AstraZeneca saw giving it a sizable share of a $6 billion (€5.5 billion) market when it acquired the asset in its $2.7 billion buyout of ZS Pharma. The transaction does not impact AstraZeneca’s financial guidance for 2015. Get the inside scoop on jobs, salaries, top office locations, and CEO insights. Our core focus is the research and development of highly selective ion-trap therapies to treat serious medical conditions. Under the terms of the agreement, AstraZeneca will acquire all of the outstanding capital stock of ZS Pharma for $90 per share in an all-cash transaction, or approximately $2.7 billion in aggregate transaction value. Out of 60 sectors in the Mergr database, life science ranked 9 in number of deals in 2015. A submission for European Marketing Application Authorisation is planned by the end of 2015. As of the expiration of the tender offer, a total of approximately 21,948,939 shares of ZS Pharma common stock were validly tendered and not withdrawn (excluding shares tendered pursuant to notices of guaranteed delivery for which certificates have not been delivered), representing approximately 86.6% of ZS Pharma’s outstanding shares. Most recently she has served as chief commercial officer and a member of the executive team of ZS Pharma (acquired by AstraZeneca), where she led efforts to transition the company from the development stage to a commercial enterprise. This deal was done in Cash. ADDRESS. Cardiovascular, metabolic disease and chronic kidney disease are key areas of focus for AstraZeneca as part of the company’s strategy for achieving scientific leadership and returning to growth. For more information please visit: www.astrazeneca.com. AstraZeneca to acquire ZS Pharma for $90 per share Acquisition includes potential best-in-class hyperkalaemia treatment currently under US FDA regulatory review Acquisition expected to contribute Product Sales from 2016 and benefit AstraZeneca’s return to growth strategy Operator of a biopharmaceutical company. After the acceptance of shares that were validly tendered and not withdrawn pursuant to the tender offer, AstraZeneca completed its acquisition of ZS Pharma through a merger of one of its subsidiaries with and into ZS Pharma. CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS. Biotech & Pharma. LONDON (AP) — Anglo-Swedish drug firm AstraZeneca has acquired U.S.-based biopharmaceutical company ZS Pharma in a deal worth $2.7 billion. AstraZeneca agree to acquire ZS Pharma Posted on November 9, 2015 AstraZeneca has announced that it has entered into a definitive agreement to acquire ZS Pharma, a biopharmaceutical company based in San Mateo, California. I have read this warning and will not be using any of the contained product information for clinical purposes. Before joining ZS Pharma, Dr. Tomasi was a Principal at Alta Partners where he contributed to investments in ZS Pharma (acquired by AstraZeneca), Lumena Pharmaceuticals (acquired by Shire), Excaliard (acquired by Pfizer), ChemGenex (acquired by Cephalon), Achaogen, Immune Design and … The transaction strengthens AstraZeneca’s cardiovascular and metabolic disease (CVMD) portfolio with the addition of the potassium-binding compound ZS-9 (sodium zirconium cyclosilicate), a potential best-in-class treatment for hyperkalaemia, a condition associated with increased mortality in patients with chronic kidney disease (CKD), diabetes mellitus (DM), and chronic heart failure (CHF). Important notice for users Robert Alexander, Chief Executive Officer, ZS Pharma, said: “This agreement will allow us to maximize the potential of ZS-9, drawing on AstraZeneca’s long-standing expertise in developing and commercializing medicines for cardiovascular and metabolic diseases. In addition, he acted as Executive Chairman and interim CEO of SARcode Biosciences. ZS Pharma (ZSPH) stock is spiking in late morning trading on Friday, after the biopharmaceutical company agreed to be acquired by AstraZeneca (AZN) for $2.7 billion. The OncAlert Oral Cancer Risk Assessment System includes a rapid, point-of-care risk assessment test (OncAlert POC Test) and…, Japan’s Fujifilm Holdings Corp will acquire a drug making business from the U.S. based Biogen Inc for about $890 million. PUBLISHED 17 December 2015. It is expected to generate Product Sales from 2016, with minimal earnings dilution over 2016 and 2017, becoming accretive to AstraZeneca’s core earnings from 2018. AstraZeneca is not responsible for the privacy policy of any third party websites. ZS-9 is under regulatory review by the US Food and Drug Administration with a Prescription Drug User Fee Act goal date of 26 May 2016. Veeva ID: Z4-25396Date of next review: August 2022. The acquisition is structured as an all-cash tender offer for all outstanding shares of ZS Pharma common stock at a price of $90 per share, followed by a merger in which each remaining untendered share of ZS Pharma common stock would be converted into the same $90 cash per share consideration as in the tender offer. Please refer to your approved national product label (SmPC) for current product information. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. INDUSTRY. AstraZeneca completes acquisition of ZS Pharma. AstraZeneca provides this link as a service to website visitors. The company has been focused on using its proprietary ion-trap technology to develop new treatments of kidney and liver diseases that are focused on addressing unmet needs in the medical community. During his time at Alta Partners, he led investments in SARcode Bioscience (acquired by Shire), Lumena Pharmaceuticals (acquired by Shire), ZS Pharma (acquired … The acquisition continues AstraZeneca’s track record of targeted business development with a focus on three main therapy areas. The company is focused on the development and commercialization of highly selective, non-systemically absorbed therapeutics to treat renal, cardiovascular, liver and metabolic diseases. Previously, Dr. Akkaraju served as a director on the Boards of Seattle Genetics, Principia Biopharma (acquired by Sanofi), Barrier Therapeutics (acquired by Stiefel Laboratories), Eyetech Pharmaceuticals (acquired by OSIP), ZS Pharma (acquired by AstraZeneca), Synageva Biopharma Corp. (acquired by Alexion Pharmaceuticals), Aravive, Inc., and Amarin Corporation. Most recently she has served as chief commercial officer and a member of the executive team of ZS Pharma (acquired by AstraZeneca), where she led efforts to transition the company from the development stage to a commercial enterprise. Alexander was CEO of ZS Pharma where he led the initial public offering and sale of ZS Pharma to AstraZeneca. AstraZeneca announced today the successful completion of the tender offer for all of the outstanding shares of ZS Pharma (NASDAQ: ZSPH) and the subsequent acquisition of ZS Pharma as previously announced in November. We look forward to joining AstraZeneca and to working together to bring this important treatment for hyperkalaemia to the global market, helping to meet an important unmet medical need for patients.”.
zs pharma acquired 2021